8-K current report · filed Jul 15, 2026

Celcuity Inc. (CELC) 8-K Current Report: July 15, 2026

Item 7.01Item 8.01Item EX-99.1CELC overview

Short answer

Celcuity Inc. (CELC) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- advanced or metastatic breast cancer.

Celcuity Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- advanced or metastatic breast cancer
  • Indication covers patients without detected PIK3CA mutations after progression on endocrine therapy
  • Approval enables commercial launch in a defined breast cancer population
  • Company webcast and presentation provided additional approval details on July 14, 2026

Item 8.01 · Other Events

  • FDA approval for REVTORPYK in HR+/HER2- advanced or metastatic breast cancer without detected PIK3CA mutation
  • Commercial launch targeted for late Q3 2026, shifting Celcuity toward revenue generation and commercialization execution
  • Supplemental NDA planned for Q3 2026 targeting PIK3CA-mutated disease, expanding potential addressable indications
  • sNDA submission based on mutant cohort results from the Phase 3 VIKTORIA-1 trial

Item EX-99.1 · Exhibit EX-99.1

  • FDA approval makes REVTORPYK Celcuity’s first commercial product for HR+/HER2-, PIK3CA wild-type advanced breast cancer
  • VIKTORIA-1 triplet reduced progression or death risk 76%, with median PFS 9.3 months versus 2.0 months
  • Doublet reduced progression or death risk 67%, with median PFS 7.4 months versus 2.0 months
  • Commercial launch targeted for late Q3 2026, creating near-term execution and market-access catalysts
  • sNDA submission planned in Q3 2026 for PIK3CA-mutated disease, potentially expanding the eligible market beyond the initial indication

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Celcuity Inc. 8-K filings

Get the next CELC 8-K as it lands

Follow CELC for push alerts, or ask the research agent what this filing means.